Leaders in Research Peptides

(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD
(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD
Highest Quality | For Research Use Only


Buy LL-37 Peptide Netherlands

LL-37, also known as cathelicidin antimicrobial peptide, is a critical component of the innate immune response. This 37-amino acid peptide has been extensively studied for its broad-spectrum antimicrobial activity and its modulatory effects on the host immune system.

LL-37 exerts its antimicrobial action primarily through disruption of microbial membranes, leading to cell death. However, it’s not solely an antimicrobial agent; Netherlands research suggests it also plays a pivotal role in immunomodulation. It can bind to specific receptors, such as the formyl peptide receptor-like 1 (FPRL1) and the purinergic receptor P2X7, triggering a cascade of cellular responses that include chemotaxis, wound healing, and angiogenesis.

Showing all 4 results

Potential Benefits of LL-37 Peptide

  • LL-37 peptide exhibits potent antimicrobial and anti-biofilm properties, making it a potential candidate for treating bacterial infections and biofilm-related diseases [1] and [2].
  • The peptide has been explored as a potential treatment for polymicrobial infected wounds due to its antimicrobial action [3].
  • LL-37 peptide is naturally secreted by human mesenchymal stem cells, contributing to their antimicrobial effect. This finding suggests the peptide’s role in innate immunity and its potential use in stem cell therapies [4] and [5].
  • Research has shown that LL-37 peptide can be successfully loaded onto nanoparticles for targeted drug delivery, indicating its potential in nanomedicine and treatment of drug-resistant bacterial infections [6].
  • According to research, the antibacterial activity of LL-37 peptide can be inhibited by salivary mucins, highlighting the importance of understanding the peptide’s interactions with other biological molecules for therapeutic applications [7].
  • In the context of cystic fibrosis, LL-37’s antimicrobial activity can be inhibited when complexed with glycosaminoglycans in the lungs. However, studies indicate this inhibition can be reversed by hypertonic saline, suggesting a potential therapeutic strategy [8].
  • Research suggests LL-37 peptide has immunomodulatory and tissue repair properties, further expanding its therapeutic potential [9].
  • There is ongoing research into the role of LL-37 peptide in COVID-19 inflammatory responses and microthrombosis, indicating its relevance in current global health issues [10].


[1] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC8227053/

[2] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC5374219/

[3] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3699762/

[4] https://www.sciencedirect.com/science/ article/pii/S2405844019363121

[5] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3293245/

[6] https://www.sciencedirect.com/science/ article/abs/pii/S1385894722005903

[7] https://pubmed.ncbi.nlm.nih.gov/18456648/

[8] https://pubmed.ncbi.nlm.nih.gov/19542465/

[9] https://pubmed.ncbi.nlm.nih.gov/25101632/

[10] https://pubmed.ncbi.nlm.nih.gov/35634307/



DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our Direct Peptides website: https://netherlands.direct-peptides.com is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.